Cancer Management and Research最新文献

{"title":"Predictive Value of Tumor ERCC1 Expression for Treatment Outcomes After Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer.","authors":"Masao Nakata, Shinsuke Saisho, Junichi Soh, Norihito Okumura, Hiroshige Nakamura, Motohiro Yamashita, Shinichi Toyooka, Hiroshi Date","doi":"10.2147/CMAR.S517916","DOIUrl":"10.2147/CMAR.S517916","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the predictive value of tumor expression of the excision repair cross-complementation group 1 gene (ERCC1) for the treatment outcomes after platinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>In this study, we conducted immunohistochemical analysis using a mouse monoclonal anti-ERCC1 antibody (clone 8F1) of operative specimens obtained from 238 patients enrolled in the SLCG0401 study which compared paclitaxel plus carboplatin (CBDCA+PTX) with uracil-tegafur (UFT) as adjuvant chemotherapy for stage IB-IIIA NSCLC. The overall survival (OS) of the patients was compared according to the ERCC1 expression status and adjuvant chemotherapy employed.</p><p><strong>Results: </strong>Of the 238 specimens, 102 (42.9%) showed a positive result for ERCC1 expression. There were no significant differences in the patient characteristics or OS between the tumor ERCC1-positive and -negative patient groups. Among the patients with ERCC1-negative tumors, there was no significant difference in the survival between patient groups treated with CBDCA+PTX and UFT (HR=0.932, 95% CI: 0.52-1.67, p=0.814). However, among the patients with ERCC1-positive tumors, CBDCA+PTX treatment tended to yield an inferior outcome, in terms of the OS, as compared with UFT treatment (HR=1.852, 95% CI: 0.92-3.73, p=0.080). Multivariate analysis showed that ERCC1 expression was not an independent predictor of the OS following CBDCA+PTX treatment in completely resected NSCLC patients.</p><p><strong>Conclusion: </strong>In completely resected NSCLC patients with positive tumor ERCC1 expression, adjuvant CBDCA+PTX treatment tended to yield an inferior outcome as compared with UFT treatment in terms of the OS. However, immunohistochemical analysis with the 8F1 antibody cannot be used for clinical decision making at this point.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1477-1486"},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Radiomics Nomogram Based on Magnetic Resonance Imaging and Clinicoradiological Factors to Predict HCC TACE Refractoriness.","authors":"YuHan Dong, Jihong Hu, Xuerou Meng, Bin Yang, Chao Peng, Wei Zhao","doi":"10.2147/CMAR.S486561","DOIUrl":"10.2147/CMAR.S486561","url":null,"abstract":"<p><strong>Purpose: </strong>This study constructs a predictive model for hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) refractoriness using a machine learning (ML) algorithm and verifies the predictive performance of different algorithms.</p><p><strong>Patients and methods: </strong>Clinical and magnetic resonance imaging (MRI) data of 131 patients (48 with TACE refractoriness) who underwent repeated TACE treatment for HCC were retrospectively collected. The training and validation cohorts comprised 104 and 27 cases, respectively, following an 8:2 ratio. Clinical imaging characteristics related to TACE refractoriness were identified through logistic regression analysis. HCC lesions on arterial phase, portal phase, delayed phase, and T2-weighted fat suppression MRI images before the first TACE were manually delineated as regions of interest. Dimension reduction was conducted using variance threshold, univariate selection, and least absolute shrinkage and selection operator methods. Relevant indices of TACE refractoriness were selected. ML algorithms, including a support vector machine, random forest, logistic regression and adaptive boosting, were used to construct the radiomics, clinical prediction, and combined models. The predictive performance of these models was evaluated using receiver operating characteristic curves. The optimal model was presented as a nomogram and verified through calibration and decision curve analyses.</p><p><strong>Results: </strong>In evaluating radiomics models for predicting TACE refractoriness in HCC, the LR-developed portal venous phase (VP) model achieved optimal single-sequence performance (training AUC: 0.896, 95% CI: 0.843-0.941; validation: 0.853, 0.727-0.965). Multisequence models significantly surpassed single-sequence counterparts, with the T2WI-FS+AP+VP+DP multisequence LR model demonstrating peak efficacy (training: 0.905, 0.853-0.949; validation: 0.876, 0.773-0.976). The integrated clinical-radiomics model demonstrated robust predictive performance, achieving a training cohort AUC of 0.955 (95% CI: 0.918-0.984) with 0.885 accuracy, 0.921 sensitivity, and 0.864 specificity, and maintained strong validation performance (AUC=0.941, 95% CI: 0.880-0.991).</p><p><strong>Conclusion: </strong>Multisequence clinical-radiomics model accurately predicts TACE refractoriness in hepatocellular carcinoma.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1441-1455"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pathogenesis and Prevention Strategies of Radiation-Induced Brain Injury.","authors":"Yong Wang, Jun Wu, Ya Wang, Weiyuan Song, Hongjian Ren, Xu Han, Xiaoqi Dong, Zhiqiang Guo","doi":"10.2147/CMAR.S525791","DOIUrl":"10.2147/CMAR.S525791","url":null,"abstract":"<p><p>Radiation-induced brain injury (RBI) encompasses the severe symptoms resulting from radiation-induced damage to the normal tissue surrounding tumors in patients undergoing radiotherapy for head and neck malignancies. The primary symptoms include skin erythema, pain, and may extend to headache, syncope, nausea, vomiting, memory impairment, alterations in mental status, visual disturbances, drowsiness, and other neurological abnormalities localized to the area of treatment. These side effects both limit the effectiveness of radiation therapy and reduce the patient's quality of life. During radiotherapy, while killing tumor cells, the radiation will damage the cerebral microvascular endothelial cells, cause cerebrovascular inflammatory response, destroy the blood-brain barrier, aggravate the cerebral oxidative stress response, and induce apoptosis of nerve cells. This review summarizes the mechanisms underlying the occurrence and progression of radiation-induced brain injury and discusses promising strategies for prevention and treatment that may be applicable to clinical patients suffering from this condition.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1433-1440"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Value of Low-Dose Spiral CT Combined with Serum CEA in the Differential Diagnosis of Early Lung Cancer.","authors":"Jianguo Jin, Liping Wu","doi":"10.2147/CMAR.S516235","DOIUrl":"10.2147/CMAR.S516235","url":null,"abstract":"<p><strong>Purpose: </strong>Early detection of lung cancer is critical to improving prognosis, yet current screening methods such as low-dose spiral CT and serum CEA each have diagnostic limitations. This study aims to analyze the clinical value of low-dose spiral CT combined with serum CEA in the differential diagnosis of early lung cancer.</p><p><strong>Materials and methods: </strong>In this retrospective study, 62 patients diagnosed with early lung cancer in our hospital from April 2022 to October 2023 were selected as the case group, and 50 patients diagnosed with benign pulmonary lesions during the same period were selected as the control group. Data from low-dose spiral CT and serum CEA levels were compared. The efficacy of low-dose spiral CT alone, serum CEA alone, and the combination of both in discriminating early lung cancer was assessed using ROC curves.</p><p><strong>Results: </strong>Low-dose spiral CT showed a sensitivity of 77.42%, a specificity of 94.00%, and an AUC of 0.8571 (95% CI: 0.7832-0.9310) in detecting early lung cancer. Serum CEA levels were significantly higher in the case group compared to the control group (P<0.05). Serum CEA yielded an AUC of 0.8661 (95% CI: 0.7964-0.9359) in distinguishing early lung cancer (P<0.0001). Low-dose spiral CT combined with serum CEA detection achieved an AUC of 0.9137 (95% CI: 0.8624-0.9650), significantly increasing the early lung cancer detection rate from 82.26% to 95.16% (P<0.05).</p><p><strong>Conclusion: </strong>Patients with early lung cancer show distinct alterations in low-dose spiral CT signs, and their serum CEA levels demonstrate a notable increase compared with those with benign pulmonary lesions. The combination of low-dose spiral CT with serum CEA can be considered in the discrimination of early lung cancer, which can markedly enhance the positive detection rate while maintaining a minimal rise in false-positive rates.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1421-1432"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.","authors":"Yuan Ye, Shuhong Li, Zhi Guo, Lijun Zhao, Huanhuan Zhou, Nan Zhong, Mingxin He, Yu J Cao, Liqiong Liu","doi":"10.2147/CMAR.S521944","DOIUrl":"10.2147/CMAR.S521944","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of novel loop-structure-based CD19/CD22 dual-target chimeric antigen receptor T-cell (CD19/CD22 BS LoopCAR-T) therapy in high-risk diffuse large B-cell lymphoma (DLBCL) presenting with hemophagocytic lymphohistiocytosis (HLH).</p><p><strong>Methods: </strong>We analyzed the clinical data of a high-risk DLBCL patient presenting with HLH treated with CD19/CD22 BS LoopCAR-T at the Affiliated Nanshan Hospital of Shenzhen University in December 2023.</p><p><strong>Results: </strong>The patient, a 59-year-old female, was diagnosed with myelodysplastic syndromes with multilineage dysplasia in October 2022. Following six cycles of azacitidine treatment, her bone marrow and hemogram returned to normal, and the disease was stable In August 2023, she presented with recurrent fever for over a month and was diagnosed with high-risk DLBCL stage IVB presenting with HLH. After receiving the HLH-1994 protocol followed by one cycle each of R-CHOP and R-DA-EPOCH regimens, the patient underwent infusion of CD19/CD22 BS LoopCAR-T cells at a dose of 1.73×10⁸ cells. She experienced a rapid response, developing grade 1 cytokine release syndrome (CRS) and no immune effector cell-associated HLH-like syndrome (IEC-HS), and achieved disease stabilization following aggressive treatment. Bone marrow and peripheral blood flow cytometry at one and three months post-CAR-T therapy showed complete remission (CR). PET-CT at three months post-CAR-T therapy also indicated CR. The patient was followed up until April 2025, and the disease-free survival time after CAR-T treatment exceeded 16 months.</p><p><strong>Conclusion: </strong>The novel CD19/CD22 BS LoopCAR-T therapy is safe and effective in treating high-risk DLBCL patients presenting with HLH.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1389-1398"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.","authors":"Fengying Gong, Yunshui Cheng, Yongchun Li, Qin Fan, Rongmei Qu, Tingyu Fan, Ying Lv, Jingxing Dai","doi":"10.2147/CMAR.S529467","DOIUrl":"10.2147/CMAR.S529467","url":null,"abstract":"<p><p>Malignant pleural effusion (MPE) is characterized by the accumulation of fluid in the chest cavity, secondary to metastasis from a primary pleural tumor or malignant neoplasms originating from other anatomical sites. MPE is associated with a poor prognosis. Consequently, timely and effective prevention and management of MPE are critical. In Western medicine, the treatment of MPE primarily involves procedures such as surgical puncture for drainage, pleural fixation, chemotherapy, and targeted therapy. In contrast, traditional Chinese medicine (TCM) offers therapeutic modalities including oral decoctions, thoracic perfusion with herbal injections, topical applications of medicinal pastes, and acupoint therapies. The TCM approaches have demonstrated satisfactory clinical outcomes. Advances in the study of TCM for managing MPE in lung tumors are expected to yield a wealth of therapeutic strategies, facilitating the development of more optimized clinical treatments.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1377-1388"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory and Nutritional Biomarker in Different Subtypes of Early Stage Diffuse Large B-Cell Lymphoma: Towards a Diagnostic Model.","authors":"Amaylia Oehadian, Stephanie Victoria Gunadi, Lusi Mersiana, Evan Susandi, Indra Wijaya, Januar Wibawa Martha, Rudi Supriyadi, Delita Prihatni","doi":"10.2147/CMAR.S527855","DOIUrl":"10.2147/CMAR.S527855","url":null,"abstract":"<p><strong>Background: </strong>Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy with distinct Germinal Center B-Cell Like (GCB) and non-GCB subtypes. Accurate subtyping is crucial due to differences in prognosis and treatment response. While gene expression profiling is the gold standard, it is often unavailable in low-resource settings. Inflammatory and nutritional biomarkers such as Systemic Immune-Inflammation Index (SII), Prognostic Nutritional Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI) offer a practical alternative. This study aims to evaluate their diagnostic potential in early-stage DLBCL subtypes.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted on 60 early stage DLBCL patients (30 GCB, 30 non-GCB) at Dr Hasan Sadikin General Hospital Bandung. Clinical characteristics, hematological parameters, and inflammation-based indices (SII, PNI, and ALI) were evaluated. Differences between subtypes were analyzed using the Mann-Whitney <i>U</i>-test, and Receiver Operating Characteristic (ROC) analysis was used to determine diagnostic performance.</p><p><strong>Results: </strong>The median SII was significantly higher in non-GCB compared with GCB (982,575; IQR: 609,112-2,239,917 vs 575,598; IQR: 454,578-886,426, p = 0.014). Conversely, PNI was higher in GCB compared to non-GCB group (49.18; IQR: 46.38-56.38 vs 45.96; IQR 40.05-52.28, p = 0.011). ALI values were also higher in the GCB than non-GCB (44.14; IQR: 27.69-67.18 vs 24.51; IQR: 14.34-42.47,p=0.003). ROC analysis revealed that ALI had the highest diagnostic accuracy (AUC = 0.724; 95% CI: 0.593-0.831), followed by SII (AUC = 0.685, 95% CI: 0.552-0.799) and PNI (AUC = 0.691 95% CI: 0.558-0.804). Optimal cut-off values were ≤1,234,133 for SII, >43.27 for PNI, and >27.41 for ALI. ALI demonstrated the best balance between sensitivity (76.7%) and specificity (63.3%), making it the most reliable marker for distinguishing DLBCL subtypes.</p><p><strong>Conclusion: </strong>SII, PNI, and ALI differ significantly between DLBCL subtypes. These findings suggest that integrating these indices into a diagnostic model could enhance risk stratification and guide therapeutic decision-making in DLBCL. Further studies with larger cohorts are warranted to validate these findings.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1361-1367"},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of Refractory Hypertension Following Radical Nephrectomy for Renal Cell Carcinoma: A Case Report from Somalia in Resource Limit Setting.","authors":"Rahmo Mohamed Ali, Abdullahi Abdirahman Omar, Ismail A Ali","doi":"10.2147/CMAR.S530092","DOIUrl":"10.2147/CMAR.S530092","url":null,"abstract":"<p><strong>Introduction: </strong>Renal cell carcinoma (RCC) is among the most prevalent kidney malignancies and is characterized by a variety of histological subtypes, with clear cell RCC being the most common subtype. Hypertension may occur as a paraneoplastic manifestation, although the resolution of refractory hypertension following radical nephrectomy remains an uncommon event. To our knowledge, this is the first documented case from a resource-limited setting in which refractory hypertension resolved completely following radical nephrectomy for RCC, underscoring unique diagnostic and therapeutic challenges in such environments.</p><p><strong>Case presentation: </strong>A 56-year-old male presented with severe uncontrolled hypertension accompanied by persistent headaches and palpitations and was unresponsive to standard anti-hypertensive therapy. Clinical examination revealed a palpable mass in the right flank. Abdominal computed tomography revealed a large, heterogeneous mass (approximately 10 cm) occupying the hepatorenal space, which was initially suggestive of pheochromocytoma. Due to limited diagnostic resources, confirmatory biochemical testing was unavailable. The patient underwent radical nephrectomy and histopathology confirmed clear cell RCC (WHO/ISUP grade 2). The patient's hypertension resolved completely postoperatively, with subsequent follow-ups demonstrating stable blood pressure and no metastatic disease.</p><p><strong>Conclusion: </strong>This case emphasizes an uncommon presentation of refractory hypertension linked directly to RCC that resolved after radical nephrectomy. This case underscores the importance of considering RCC as a differential diagnosis for refractory hypertension, particularly in resource-limited settings where advanced diagnostics and recent surgical are unavailable.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1369-1375"},"PeriodicalIF":2.5,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of Combined Systemic Immune-Inflammatory Index (SII) and Prognostic Nutritional Index (PNI) in Solid Tumor.","authors":"Yan Zhang, Min Tang, Qian-Hui Gu, Li-Na Zhou, Min-Bin Chen","doi":"10.2147/CMAR.S523419","DOIUrl":"10.2147/CMAR.S523419","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and nutrition status were the essential factors for cancer initiation and progression. Previous studies have confirmed systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) could predict the prognosis of cancer patients. The aim of this study was to evaluate the pre-treatment SII and PNI in predicting outcomes in different cancers.</p><p><strong>Methods: </strong>The retrospective study included 508 cancer cases diagnosed between June 2013 and June 2022. The pre-treatment SII and PNI were calculated from peripheral blood samples, and the cutoff value was determined by receiver operating characteristic (ROC). The association of SII, PNI with clinicopathological characters and prognosis were assessed by Cox regression and Kaplan-Meier methods.</p><p><strong>Results: </strong>The ideal preoperative SII and PNI cutoff values were 792.0 and 49.825, respectively. High SII group as well as low PNI group had worse prognosis. Patients satisfied both high SII and low PNI had the lowest overall survival (OS) rate (<i>p</i> < 0.001). Multivariable Cox regression analysis identified that the tumor stage (<i>p</i> < 0.001), BMI (<i>p</i> = 0.042), SII (<i>p</i> = 0.001) and AGR (<i>p</i> = 0.047) were independently prognostic markers for OS.</p><p><strong>Conclusion: </strong>High level of pretreatment SII may be an independent prognostic factor for cancer patients. Patients with both high SII and low PNI had the worst prognosis.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1351-1359"},"PeriodicalIF":2.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway [Retraction].","authors":"","doi":"10.2147/CMAR.S551287","DOIUrl":"https://doi.org/10.2147/CMAR.S551287","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/CMAR.S261182.].</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1313-1314"},"PeriodicalIF":2.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12241224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}